AUG 07, 2018 08:30 PM PDT

Potential Bcl-2 Targeted Therapy for Relapsed Multiple Myeloma Patients

In June 2018, a new first of its kind drug class for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) was approved by the Food and Drug Administration in the United States.  The target of this new drug class is Bcl-2, which is an apoptotic, or programmed cell death, regulator.  Bcl-2 controls cell death through mitochondrial membrane permeability mechanisms with caspases.  Bcl-2 is located on chromosome 18, and is considered an oncogene; this sequence can, and is, involved in translocations or mutations resulting in deregulation of expression in tumorigenesis.  Tumor cells must survive inhospitable conditions including hypoxia and loss of nutrient supply when they become advanced enough; each of these contribute to tumor cell damage susceptibility and apoptosis.  Tumor cells must adapt by gaining mutations that inhibit that apoptotic process which is what happens with Bcl-2 mutations. 

Bcl-2 family members, there are reported to be about 20 total related proteins, act to create protein channels or pores within the mitochondrial membrane allowing the release of factors like Cytochrome C.  These factors are intermediaries as part of one apoptotic pathway.  When Bcl-2 expression is affected by mutation, these factors cannot be released as a part of the apoptosis mechanism of the cell.

In mutated lymphocytic cells, there is high level of expression of proapoptotic proteins at the ready but they are stuck waiting by the blocked Bcl-2 pathway.  Patients with these primed mutated lymphocytes, like those with CLL, readily die when another apoptotic agent outside of that Bcl-2 mediated pathway is introduced in conjunction with this new drug class. 

Additional investigations are being made using Bcl-2 targeted drugs for other conditions like Multiple Myeloma (MM), which does not involve an altered chromosome 18; MM cells are plasma cells with a translocation between chromosomes 11 and 14.  However, one group of researchers published their investigation in Leukemia on August 3, 2018.  MM patients have overexpression of anti-apoptotic proteins like Bcl-2; they found that combination therapy which included venetoclax, the Bcl-2 targeted drug approved by the FDA in June, had a promising response rate in relapsed myeloma patients.  This type of pretreated myeloma patient has few options for disease free survival long term.  This new approach may prove to be clinically relevant in the near future after further research is conducted.  

Sources: Leukemia, Blood, FDA, BBA Molecular Cell Research,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
JUN 05, 2018
Cell & Molecular Biology
JUN 05, 2018
Mechanism of Aspirin's Anti-Colon Cancer Effects Revealed
For some people, aspirin can help prevent colon cancer; now researchers have learned more about how that happens....
JUN 27, 2018
Immunology
JUN 27, 2018
Immune Cells Responsible for Chemo-induced Diarrhea
While studying specific immune cells in the context of chronic itching in the skin, two Washington University School of Medicine scientists discovered that...
JUL 17, 2018
Health & Medicine
JUL 17, 2018
Can the Keto Diet Make Cancer Treatment More Effective?
It’s been said that “you are what you eat” but with so many diet plans and trends, it can be hard to choose. Paleo, keto, Mediterranean,...
JUL 24, 2018
Cancer
JUL 24, 2018
Veterans with Cancer Get Streamlined Access to NCI Clinical Trials
Veterans with cancer, and the VA that cares for them, struggle to navigate the complex world of clinical trials but a collaborative agreement between VA and NCI could fix that....
AUG 21, 2018
Cancer
AUG 21, 2018
'Zombie' gene returns to life and kills cancer in elephants
Researchers have discovered a gene that can protect elephants from cancer. An estimated 17 percent of humans worldwide die from cancer, but less than five ...
OCT 06, 2018
Genetics & Genomics
OCT 06, 2018
Genetic Mutation Linked to Increased Pancreatic Cancer Risk in Women
In a first, researchers have found a genetic mutation that has a sex-specific effect on pancreatic cancer risk....
Loading Comments...